[Research] Celltrion (068270) – IBK Securities | New Biosimilar Mix Expansion · Operating Leverage · H2 Margin Expansion / 2026-05-07
Brokerage : IBK Securities Analyst : Lee-soo Jung Investment Rating : BUY (Maintained) Target Price : KRW 250,000 (Maintained) Core Momentum : Expanding sales share of new biosimilar products and operating leverage from top-line growth supporting progressive margin improvements in the second half 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market Opportunities &…